20May 2023
SUNLIGHT illuminates the activity of bevacizumab

SUNLIGHT illuminates the activity of bevacizumab

In patients with metastatic colorectal cancer (CRC) who experience disease progression on initial chemotherapy, the standard treatment is to switch to alternative regimens such as trifluridine plus tipiracil (FTD-TPI). However, the effectiveness of combining targeted therapies with FTD-TPI has been uncertain. The phase III SUNLIGHT trial has now provided data showing that the addition of bevacizumab to FTD-TPI leads to improved outcomes for these patients. This finding suggests that combining bevacizumab with FTD-TPI could be a more effective treatment approach for patients with metastatic CRC.

  • #oncology

Like

Save

Share